ExpreS2ion Biotech Holding AB (EXPRS2) AI Stock Analysis

• Market Cap: kr18.71M
• Dividend Yield: N/A
• Average Volume (3M): 19.88K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.41
• Revenue Growth: 8.46%
• EPS Growth: 11.73%
• Country: SE
• Employees: 20
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -2.41
• Shares Outstanding: 3,530,233
• 10 Day Avg. Volume: 26,629
• 30 Day Avg. Volume: 19,883
• PEG Ratio: 0.03
• Price to Book (P/B): 1.27
• Price to Sales (P/S): 12.37
• P/FCF Ratio: -1.11
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): -27
• Revenue Forecast (FY): kr10.00M

• Rating: 43 Neutral
• Price Target: kr5.00 ▼(-70.76% Downside)
• Action: Upgraded Date: 03/04/26
• Date: Action: Upgraded 03/04/26

The score is driven primarily by weak financial performance (persistent losses and negative free cash flow despite low leverage) and very bearish technicals (price far below key moving averages with negative MACD). Valuation provides limited support because the negative P/E reflects loss-making operations and no dividend yield is available.

Positive Factors

Proprietary protein expression platform

Owning a specialized insect-cell ExpreS2 platform is a durable competitive asset for producing complex antigens and VLP components. This technical moat supports recurring service demand, enables differentiation vs generic CDMOs, and underpins long-term partnership and licensing opportunities.

Low financial leverage

Low debt provides structural financial flexibility and limits interest burden, giving management more options to fund operations via equity or strategic deals. This reduces insolvency risk and preserves capacity to pursue partnerships or raise capital when needed over the medium term.

Diversified revenue channels: services and partnering

A dual model of contracted platform services plus potential partnering/licensing creates multiple durable revenue pathways. Services can provide steady contract income while partnerships offer milestone/royalty upside, reducing reliance on a single monetization route over 2–6 months and beyond.

Negative Factors

Consistent negative operating and free cash flow

Persistent negative operating and free cash flow indicates the business consumes cash rather than funds itself, creating ongoing funding needs. Continued cash burn increases probability of future equity raises or dilutive financings and constrains strategic investment in platform scaling or pipeline advancement.

Shrinking equity and contracting assets

Material declines in equity and assets reflect cumulative losses that erode the balance sheet buffer. A weakened capital base limits borrowing capacity, raises counterparty concerns, and increases the company's sensitivity to further setbacks or larger-than-expected funding needs.

Small, volatile, declining revenue and persistent losses

Volatile, small, and recently declining revenues with recurring operating losses imply limited internal ability to scale profitability. Without sustainable revenue growth or margin improvement, reliance on external funding and partner deals will persist, constraining long-term operational independence.

ExpreS2ion Biotech Holding AB Business Overview & Revenue Model

Company Description

ExpreS2ion Biotech Holding AB (publ), through its subsidiary, ExpreS2 ion Biotechnologies ApS, develops and produces complex proteins for vaccines and diagnostics in Denmark. The company develops capsid virus-like particle COVID-19 vaccine, which is in Phase II clinical trial. It also develops influenza and breast cancer vaccine, which is in Phase II clinical trial, as well as develops malaria vaccine. In addition, the company licenses its ExpreS2 platform to research institutes and pharmaceutical companies. ExpreS2ion Biotech Holding AB (publ) was founded in 2015 is based in Horsholm, Denmark.

How the Company Makes Money

ExpreS2ion Biotech generates revenue primarily through its proprietary ExpreS2 platform, which is licensed to pharmaceutical and biotech companies for the production of antibodies and proteins. The company earns money from licensing agreements, where clients pay fees for using the ExpreS2 technology, as well as milestone payments and royalties based on the commercial success of products developed using its platform. Additionally, ExpreS2ion may engage in collaborative agreements with strategic partners that can provide funding and shared resources for research and development projects, further enhancing its revenue potential.

ExpreS2ion Biotech Holding AB Financial Statement Overview

Summary

Overall financial quality is weak: revenue is small and volatile with recent declines, profitability remains deeply negative despite some loss narrowing, and operating/free cash flow are consistently negative (cash burn worsened again in 2025). The main offset is low leverage, but shrinking equity/assets and ongoing cash consumption point to continued funding risk.

Income Statement

Revenue remains small and has been volatile, with declines in 2024 and again in 2025 (annual revenue down ~4% in 2025 after a steep drop in 2024). Profitability is weak: the company has posted sizable operating and net losses every year, and margins have been deeply negative in the most recent periods. A key positive is that net losses narrowed versus 2023, but the overall earnings profile remains structurally loss-making with limited evidence of durable improvement.

Balance Sheet

Leverage is low, with total debt staying modest relative to equity across the period (debt-to-equity around ~2–3% in recent years), which provides financial flexibility. However, the equity base and total assets have contracted materially from 2021–2024, consistent with ongoing losses and cash burn. Returns on equity have been meaningfully negative throughout, highlighting that the balance sheet strength is being pressured by continued operating deficits.

Cash Flow

Cash generation is a clear weak point: operating cash flow and free cash flow have been consistently negative, indicating the business is consuming cash rather than funding itself internally. While cash burn improved materially from 2022–2023 to 2024, it worsened again in 2025 (free cash flow down ~13% year over year). Cash flow trends suggest continued dependence on external funding unless revenues scale or costs come down.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	3.66M	3.01M	7.05M	5.09M	12.23M
Gross Profit	-42.84M	-2.67M	3.40M	5.00K	4.72M
EBITDA	-51.35M	-64.34M	-102.45M	-124.49M	-46.38M
Net Income	-38.09M	-36.04M	-91.40M	-118.61M	-43.92M
Balance Sheet
Total Assets	65.11M	104.53M	78.69M	137.36M	151.96M
Cash, Cash Equivalents and Short-Term Investments	47.55M	81.54M	57.60M	110.97M	138.88M
Total Debt	2.21M	1.80M	1.71M	1.85M	2.11M
Total Liabilities	29.42M	40.11M	13.33M	34.04M	11.61M
Stockholders Equity	35.69M	64.80M	65.36M	103.33M	140.35M
Cash Flow
Free Cash Flow	-40.90M	-34.80M	-102.90M	-100.00M	-46.36M
Operating Cash Flow	-40.90M	-33.93M	-100.89M	-99.61M	-45.65M
Investing Cash Flow	0.00	21.27M	-2.02M	105.33M	-100.92M
Financing Cash Flow	10.78M	34.87M	47.84M	61.46M	74.55M

ExpreS2ion Biotech Holding AB Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 17.10
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:EXPRS2, the sentiment is Negative. The current price of 17.1 is above the 20-day moving average (MA) of 12.13, above the 50-day MA of 14.27, and below the 200-day MA of 19.34, indicating a bearish trend. The MACD of -2.70 indicates Positive momentum. The RSI at 17.32 is Positive, neither overbought nor oversold. The STOCH value of 3.25 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:EXPRS2.

ExpreS2ion Biotech Holding AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SPRINT	79 Outperform	kr196.26M	1.48	-264.12%	―	-17.80%	-11.96%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ONCOZ	47 Neutral	kr73.35M	-5.14	-202.18%	―	―	20.55%
STABL	45 Neutral	kr11.52M	-2.37	-84.80%	―	―	64.02%
ACOU	45 Neutral	kr62.01M	-4.39	-79.59%	―	59.70%	44.60%
EXPRS2	43 Neutral	kr18.71M	-1.19	-88.65%	―	8.46%	11.73%
LARK	43 Neutral	kr41.58M	-1.97	―	8.47%	-94.12%	-25.83%